| Product Includes | Product # | Quantity | Mol. Wt | Isotype/Source |
|---|---|---|---|---|
| Phospho-CYLD (Ser418) Antibody | 4500 | 20 µl | 108 kDa | Rabbit |
| STAMBP Antibody | 5245 | 20 µl | 50 kDa | Rabbit |
| A20/TNFAIP3 (D13H3) Rabbit mAb | 5630 | 20 µl | 82 kDa | Rabbit IgG |
| UCHL1 (D3T2E) XP® Rabbit mAb | 13179 | 20 µl | 27 kDa | Rabbit IgG |
| HAUSP (D17C6) XP® Rabbit mAb | 4833 | 20 µl | 135, 140 kDa | Rabbit IgG |
| USP9X Antibody | 5751 | 20 µl | 270 kDa | Rabbit |
| CYLD (D1A10) Rabbit mAb | 8462 | 20 µl | 108 kDa | Rabbit IgG |
| UCHL3 (D25E6) Rabbit mAb | 8141 | 20 µl | 27 kDa | Rabbit IgG |
| USP10 (D7A5) Rabbit mAb | 8501 | 20 µl | 110 kDa | Rabbit IgG |
| Anti-rabbit IgG, HRP-linked Antibody | 7074 | 100 µl | Goat |
Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.
Description
The DUB Antibody Sampler Kit offers an economical means of evaluating the presence and status of selected DUB enzymes. This kit contains enough primary antibody to perform two western blot experiments per primary.
Storage
Background
Ubiquitinating enzymes (UBEs) catalyze protein ubiquitination, a reversible process countered by deubiquitinating enzyme (DUB) action (1,2). CYLD deubiquitinase regulates inflammation and cell proliferation by down regulating NF-κB signaling through removal of ubiquitin chains from several NF-κB pathway proteins (3,4). Phosphorylation at Ser418 decreases CYLD deubiquitinase activity and is important for IKKε-driven transformation (5). STAM-binding protein (STAMBP or AMSH) is an endosomal DUB that preferentially displays ubiquitin isopeptidase activity toward K63-linked chains (6,7). The amino-terminus of A20 contains deubiquitinating activity for Lys63 branches, such as those found in TRAF6 and RIP, while the carboxyl-terminus contains ubiquitin ligase activity for Lys48 branches of the same substrates and leads to their degradation (8). Both enzymes have been implicated in neurodegenerative diseases (9-11) and play a role in the regulation of neuronal development and spermatogenesis (10,13,14). UCHL1 binds monoubiquitin and UCHL3 shows affinity for both ubiquitin and NEDD8, a ubiquitin-like molecule (11,12). HAUSP can bind and deubiquitinate the p53 transcription factor and an associated regulator protein Mdm2, thereby stabilizing both proteins (15,16). HAUSP also modifies other ubiquitinated proteins such as members of the FoxO family of forkhead transcription factors and the mitotic stress checkpoint protein CHFR (17,18). USP10 appears to be regulated through both protein-protein interactions and phosphorylation. Interaction of USP10 with Ras-GAP SH3 domain binding protein (G3BP) inhibits its ability to disassemble ubiquitin chains (19). ATM-mediated phosphorylation at Thr42 and Ser337 stabilizes USP10, promoting redistribution from the cytoplasm to the nucleus, where it functions in p53 deubiquitination, stabilization, and activation in response to genotoxic stress (20). USP9X possesses a well-conserved catalytic domain with cysteine peptidase activity, which allows for cleavage of ubiquitin and polyubiquitin conjugates. While USP9X expression has been shown to be critical for normal mammalian development (21-23), many of its substrates are only beginning to be elucidated.
- Nijman, S.M. et al. (2005) Cell 123, 773-86.
- Nalepa, G. et al. (2006) Nat Rev Drug Discov 5, 596-613.
- Regamey, A. et al. (2003) J Exp Med 198, 1959-64.
- Glittenberg, M. and Ligoxygakis, P. Fly (Austin) 1, 330-2.
- Hutti, J.E. et al. (2009) Mol Cell 34, 461-72.
- McCullough, J. et al. (2006) Curr Biol 16, 160-5.
- Kim, M.S. et al. (2006) Biochem Biophys Res Commun 351, 612-8.
- Lin, S.C. et al. (2008) J Mol Biol 376, 526-40.
- Leroy, E. et al. (1998) Nature 395, 451-2.
- Kurihara, L.J. et al. (2001) Hum Mol Genet 10, 1963-70.
- Osaka, H. et al. (2003) Hum Mol Genet 12, 1945-58.
- Wada, H. et al. (1998) Biochem Biophys Res Commun 251, 688-92.
- Sakurai, M. et al. (2006) J Cell Sci 119, 162-71.
- Kwon, J. (2007) Exp Anim 56, 71-7.
- Li, M. et al. (2002) Nature 416, 648-53.
- Brooks, C.L. et al. (2007) Oncogene 26, 7262-6.
- van der Horst, A. et al. (2006) Nat Cell Biol 8, 1064-73.
- Oh, Y.M. et al. (2007) Biochem Biophys Res Commun 357, 615-9.
- Soncini, C. et al. (2001) Oncogene 20, 3869-79.
- Yuan, J. et al. (2010) Cell 140, 384-96.
- Pantaleon, M. et al. (2001) Mech Dev 109, 151-60.
- Noma, T. et al. (2002) Mech Dev 119 Suppl 1, S91-5.
- Xu, J. et al. (2005) J Neurosci Res 80, 47-55.
Background References
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.